var data={"title":"Albuterol (salbutamol): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Albuterol (salbutamol): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5577?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=albuterol-salbutamol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Albuterol (salbutamol): Patient drug information&quot;</a> and <a href=\"topic.htm?path=albuterol-salbutamol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Albuterol (salbutamol): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130976\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ProAir HFA;</li>\n      <li>ProAir RespiClick;</li>\n      <li>Proventil HFA;</li>\n      <li>Ventolin HFA;</li>\n      <li>VoSpire ER [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130977\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Airomir;</li>\n      <li>Ventolin Diskus;</li>\n      <li>Ventolin HFA;</li>\n      <li>Ventolin I.V. Infusion;</li>\n      <li>Ventolin Nebules P.F.;</li>\n      <li>Ventolin Respirator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131027\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Beta<sub>2</sub> Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130981\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchospasm:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler (MDI) or dry powder inhaler (90 mcg/actuation):</i> 2 inhalations every 4 to 6 hours as needed (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler (100 mcg/actuation): </i>Airomir [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute treatment: 1 to 2 inhalations; additional inhalations may be necessary every 4 to 6 hours as needed if inadequate relief however patients should be advised to promptly consult health care provider or seek medical attention if no relief from acute treatment (additional inhalations or more frequent administration is not recommended)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance (in combination with corticosteroid therapy): 1 to 2 inhalations every 4 to 6 hours as needed (maximum: 8 inhalations daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dry powder inhaler (200 mcg/inhalation): </i>Ventolin Diskus [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute treatment: 1 inhalation (200 mcg) as needed; maximum: 4 inhalations (800 mcg)/day; patient should be advised to promptly consult health care provider or seek medical attention if prior dose fails to provide adequate relief or if control of symptoms lasts &lt;3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance (in combination with corticosteroid therapy): 1 inhalation (200 mcg) every 4 to 6 hours; maximum: 4 inhalations (800 mcg)/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nebulization solution:</i> 2.5 mg 3 to 4 times daily as needed; Quick relief: 1.25 to 5 mg every 4 to 8 hours as needed (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: <b>Note:</b> Oral is not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regular release:</i> 2 to 4 mg/dose 3 to 4 times daily; maximum dose not to exceed 32 mg daily (divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release:</i> 8 mg every 12 hours; maximum dose not to exceed 32 mg/day (divided doses). A 4 mg dose every 12 hours may be sufficient in some patients, such as adults of low body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV continuous infusion [Canadian product]: Severe bronchospasm and status asthmaticus: Initial: 5 mcg/minute; may increase up to 10 to 20 mcg/minute at 15- to 30-minute intervals if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Exacerbation of asthma (acute, severe) </b> (NAEPP 2007): Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler or dry powder inhaler (90 mcg/actuation):</i> 4 to 8 inhalations every 20 minutes for up to 4 hours, then every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nebulization solution:</i> 2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to 10 mg every 1 to 4 hours as needed, <b>or</b> 10 to 15 mg/hour by continuous nebulization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Exercise-induced bronchospasm (prevention):</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler or dry powder inhaler (90 mcg/actuation):</i> 2 inhalations 5 minutes prior to exercise (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler (100 mcg/actuation): </i>Airomir [Canadian product]: 2 inhalations 30 minutes prior to exercise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dry powder inhaler (200 mcg/inhalation): </i>Ventolin Diskus [Canadian product]: 1 inhalation (200 mcg) 15 minutes before exercise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia (off-label use):</b> Inhalation:<i> Nebulization solution:</i> 10 to 20 mg over 10 minutes in combination with other recommended therapies (Putcha 2007; Wong 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131004\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=albuterol-salbutamol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Albuterol (salbutamol): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchospasm:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler or dry powder inhaler (90 mcg/actuation)</i> (NAEPP 2007): Quick relief: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler (100 mcg/actuation): </i>Airomir [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Acute treatment: 1 inhalation; additional inhalations may be necessary every 4 to 6 hours as needed if inadequate relief; however, patients should be advised to promptly consult health care provider or seek medical attention if no relief from acute treatment (additional inhalations or more frequent administration is not recommended)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance (in combination with corticosteroid therapy): 1 inhalation every 4 to 6 hours as needed (maximum: 4 inhalations daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dry powder inhaler (200 mcg/inhalation): </i>Ventolin Diskus [Canadian product]: Children &ge;4 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nebulization solution:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 12 years: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">10 to 15 kg: 0.63 to 1.25 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;15 kg: 0.63 to 2.5 mg 3 to 4 times daily as needed; titrate dose based on clinical response (maximum: 10 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 2.5 mg 3 to 4 times daily as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative recommendations (NAEPP 2007): Quick relief:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;4 years of age: 0.63 to 2.5 mg every 4 to 6 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;5 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: <b>Note:</b> Oral is not the preferred route for treatment of asthma; inhalation via nebulization or MDI is preferred (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regular release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to 6 years: 0.1 to 0.2 mg/kg/dose 3 times daily (maximum: 12 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 12 years: 2 mg/dose 3 to 4 times daily (maximum: 24 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;12 years and Adolescents: 2 to 4 mg/dose 3 to 4 times daily (maximum: 32 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 12 years: 4 mg every 12 hours (maximum: 24 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;12 years and Adolescents: 8 mg every 12 hours (maximum: 32 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Exacerbation of asthma (acute, severe) </b> (NAEPP 2007): Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler or dry powder inhaler (90 mcg/actuation):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: 4 to 8 inhalations every 20 minutes for 3 doses, then every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nebulization solution:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: 0.15 mg/kg (minimum: 2.5 mg) every 20 minutes for 3 doses, then 0.15 to 0.3 mg/kg (maximum: 10 mg) every 1 to 4 hours as needed, <b>or</b> 0.5 mg/kg/hour by continuous nebulization</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Exercise-induced bronchospasm (prevention):</b> Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler or dry powder inhaler (90 mcg/actuation):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;4 years: 1 to 2 inhalations 5 minutes prior to exercise (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;4 years and Adolescents: 2 inhalations 5 minutes prior to exercise (NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Metered-dose inhaler (100 mcg/actuation): </i>Airomir [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 11 years: 1 inhalation 30 minutes prior to exercise</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dry powder inhaler (200 mcg/inhalation): </i>Ventolin Diskus [Canadian product]: Children &ge;4 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130982\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Inhalation:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchospasm (treatment):</b> Oral, regular release: 2 mg 3 to 4 times daily; maximum: 8 mg 4 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130983\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. No dosage adjustment required in patients on hemodialysis, peritoneal dialysis, or CRRT (Aronoff 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671334\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130951\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProAir RespiClick: 90 mcg/actuation (1 ea) [contains milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ProAir HFA: 90 mcg/actuation (8.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proventil HFA: 90 mcg/actuation (6.7 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ventolin HFA: 90 mcg/actuation (8 g, 18 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.63 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 0.083% [2.5 mg/3 mL] (3 mL); 0.5% [2.5 mg/0.5 mL] (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VoSpire ER: 4 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VoSpire ER: 8 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130935\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20995164\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">ProAir HFA 8.5 g canisters, ProAir RespiClick 0.65 g inhaler, Proventil HFA 6.7 g canisters, and Ventolin HFA 18 g canisters contain 200 inhalations. Ventolin HFA 8 g canisters contain 60 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950005\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol Solution, inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Airomir: 100 mcg/inhalation (3.7 g) [chlorofluorocarbon free; 100 metered actuations]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Airomir: 100 mcg/inhalation (6.7 g) [chlorofluorocarbon free; 200 metered actuations]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol Powder Breath Activated, Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ventolin Diskus: 200 mcg/dose (60 ea) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Injection, as sulphate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ventolin I.V.: 1 mg/1mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130955\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infusion solution [Canadian product]: Do not inject undiluted. Reduce concentration by at least 50% before infusing. Administer as a continuous infusion via infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metered-dose inhalers: Shake well before use; prime prior to first use, and whenever inhaler has not been used for &gt;2 weeks or when it has been dropped, by releasing 3 to 4 test sprays into the air (away from face). Airomir [Canadian product] labeling recommends releasing a minimum of 4 test sprays when priming. HFA inhalers should be cleaned with warm water at least once per week; allow to air dry completely prior to use. A spacer device or valved holding chamber is recommended for use with metered-dose inhalers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dry powder inhalers:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Proair Respiclick: Inhaler device is breath-actuated; does not require priming. Do not use with spacer or volume holding chamber. Keep inhaler clean and dry by wiping with dry cloth or tissue as needed; do not wash or put any part of inhaler in water.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ventolin Diskus [Canadian product]: For oral inhalation route only. To activate Diskus, patient should slide lever using the thumb grip away from them as far as it will go (click should be heard). Before inhaling the dose, breathe out fully; do not exhale into the Diskus device. Bring mouthpiece to lips and inhale steadily and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. To close Diskus slide thumb grip back as far as it will go towards its original position. To prevent a wasted dose, the lever should not be manipulated until administration of next dose. Diskus counts down from 60 to 1 and when 5 doses remain the numbers appear in red. Diskus should be kept dry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization solution: Concentrated solutions (&ge;0.5%) should be diluted prior to use; adjust nebulizer flow to deliver dosage over 5 to 15 minutes; avoid contact of the dropper tip (multidose bottle) with any surface, including the nebulizer reservoir and associated ventilator equipment. Blow-by administration is not recommended; use a mask device if patient unable to hold mouthpiece in mouth for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Do not crush or chew extended release tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130954\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchospasm:</b> Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Exercise-induced bronchospasm:</b> Prevention of exercise-induced bronchospasm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816100\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Asthma (children younger than 4 years) (metered-dose inhaler); Hyperkalemia (Inhalation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131035\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuterol may be confused with Albutein, atenolol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proventil may be confused with Bentyl, PriLOSEC, Prinivil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Salbutamol may be confused with salmeterol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ventolin may be confused with phentolamine, Benylin, Vantin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130942\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidence of adverse effects is dependent upon age of patient, dose, and route of administration. Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Excitement (children and adolescents 2 to 14 years: 20%), nervousness (4% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (&ge;5% to 38%; frequency increases with age)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&ge;5% to 21%), rhinitis (5% to 16%), bronchospasm (8% to 15%; exacerbation of underlying pulmonary disease), pharyngitis (14%), exacerbation of asthma (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (&le;7%), hypertension (1% to 3%), chest pain (&lt;3%), edema (&lt;3%), extrasystoles (&lt;3%), chest discomfort, flushing, palpitations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Shakiness (children and adolescents 6 to 14 years: 9%), headache (3% to 7%), dizziness (&lt;7%), insomnia (1% to 3%), anxiety (&lt;3%), ataxia (&lt;3%), depression (&lt;3%), drowsiness (&lt;3%), rigors (&lt;3%), voice disorder (&lt;3%), hyperactivity (children and adolescents 6 to 14 years: 2%), malaise (2%), pain (2%), migraine (&le;2%), emotional lability (1%), fatigue (1%), restlessness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&lt;3%), skin rash (&lt;3%), urticaria (&le;2%), pallor (children 2 to 6 years: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose (10%), diabetes mellitus (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2% to 10%), vomiting (3% to 7%), unpleasant taste (inhalation site, 4%), gastroenteritis (3%), increased appetite (children and adolescents 6 to 14 years: 3%), viral gastroenteritis (1% to 3%), diarrhea (&lt;3%), eructation (&lt;3%), flatulence (&lt;3%), glossitis (&lt;3%), xerostomia (&lt;3%), gastrointestinal symptoms (children 2 to 6 years: 2%), dyspepsia (1% to 2%), anorexia (children 2 to 6 years: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&le;3%), difficulty in micturition</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit (7%), decreased hemoglobin (7%), decreased white blood cell count (4%), lymphadenopathy (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (5%), increased serum AST (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Cold symptoms (3%), infection (&lt;3%; skin/appendage: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction (HFA inhaler: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps (1% to 7%; frequency increases with age), musculoskeletal pain (3% to 5%), back pain (2% to 4%), hyperkinesia (&le;4%), leg cramps (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (children 2 to 6 years: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (&le;4%), ear disease (&lt;3%), otalgia (&lt;3%), tinnitus (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Throat irritation (10%), viral upper respiratory tract infection (7%), respiratory tract disease (6%), nasopharyngitis (&ge;5%; children: 2%), oropharyngeal pain (&ge;5%; children: 2%), sinusitis (&ge;5%), upper respiratory tract inflammation (5%), cough (&ge;3%), flu-like symptoms (3%), dyspnea (&lt;3%), laryngitis (&lt;3%), oropharyngeal edema (&lt;3%), pulmonary disease (&lt;3%), bronchitis (&ge;2%), increased bronchial secretions (2%), wheezing (1% to 2%), epistaxis (children and adolescents 6 to 14 years: 1%), nasal congestion (1%), sinus headache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&ge;5% to 6%), accidental injury (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angina pectoris, angioedema, atrial fibrillation, dysgeusia, exacerbation of diabetes mellitus, gag reflex, hoarseness, hyperglycemia, hypokalemia, hypotension, irritability, ketoacidosis, lactic acidosis, metabolic acidosis, muscle spasm (children and adolescents 6 to 14 years), mydriasis (children and adolescents 6 to 14 years), oropharyngeal irritation, paradoxical bronchospasm, peripheral vasodilation, stomach pain (children and adolescents 6 to 14 years), supraventricular tachycardia, tongue ulcer, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130958\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation, Oral: Hypersensitivity to albuterol or any component of the formulation; severe hypersensitivity to milk proteins (dry powder inhalers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Ventolin: Hypersensitivity to albuterol or any component of the formulation; tachyarrhythmias; risk of abortion during first or second trimester</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation: Tocolytic use in patients at risk of premature labor or threatened abortion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130939\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents (may be fatal); this should be distinguished from inadequate response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Albuterol is a short-acting beta<sub>2</sub>-agonist (SABA) that should be used as needed for quick relief of asthma symptoms. Based on a step-wise treatment approach using asthma guidelines, monotherapy without concurrent use of a long-term controller medication should only be reserved for patients with mild, intermittent forms of asthma without the presence of risk factors (Step 1 and/or exercise-induced) (GINA 2016; NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, heart failure); beta-agonists may produce ECG changes (flattening of the T wave, prolongation of the QTc interval, ST segment depression) and/or cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta<sub>2</sub>-agonists may also increase risk of arrhythmias. In a scientific statement from the American Heart Association, albuterol has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate to major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose and aggravate preexisting diabetes and ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta<sub>2</sub>-agonists may decrease serum potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use spacer for children &lt;5 years of age and consider adding a face mask for infants and children &lt;4 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Powder for oral inhalation contains lactose; hypersensitivity reactions (eg, anaphylaxis, angioedema, pruritus, and rash) have been reported in patients with milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298694\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130944\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9396&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130947\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130961\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. Albuterol crosses the placenta (Boulton 1997). Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to albuterol has been established. The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Albuterol is the preferred short acting beta-agonist when treatment for asthma is needed during pregnancy (ACOG 2008; GINA 2016; NAEPP 2007). If high doses are required during labor and delivery, monitoring of glucose concentrations in the newborn for 24 hours is recommended, especially in preterm infants (GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Albuterol may affect uterine contractility. Maternal pulmonary edema and other adverse events have been reported when albuterol was used for tocolysis. Albuterol is not approved for use as a tocolytic; use caution when needed to treat bronchospasm in pregnant women. Use of the injection (Canadian product; not available in the US.) is specifically contraindicated in women during the first or second trimester who may be at risk of threatened abortion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16137852\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if albuterol is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The amount of albuterol available systemically following inhalation is significantly less in comparison to oral doses. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Women with asthma should be encouraged to breastfeed (GINA 2016). Use of albuterol is generally considered acceptable in breastfeeding women when used in usual doses (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130949\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; serum glucose, serum potassium, serum creatinine; asthma symptoms; arterial or capillary blood gases (if patients condition warrants)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130938\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Relaxes bronchial smooth muscle by action on beta<sub>2</sub>-receptors with little effect on heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130957\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization/oral inhalation: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CFC-propelled albuterol: 10 minutes (peak plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation powder: 30 minutes (peak plasma concentration)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HFA inhalers: 25 minutes (peak plasma concentration); ~56 minutes (peak FEV<sub>1</sub> effect)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Nebulization/oral inhalation: 2 to 6 hours; Oral: Immediate release: 4 to 6 hours; extended release tablets: Up to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to an inactive sulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Inhalation: 3.8 to ~5 hours; Oral: 3.7 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (30% as unchanged drug); feces (&lt;20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130960\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ProAir RespiClick Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (1): $67.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (ProAir HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (8.5 g): $71.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Proventil HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (6.7 g): $95.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Ventolin HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">108 (90 Base) mcg/ACT (8 g): $25.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Albuterol Sulfate Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.63 mg/3 mL (3 mL): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/3 mL (3 mL): $1.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">(2.5 MG/3ML) 0.083% (3 mL): $1.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">(5 MG/ML) 0.5% (1): $0.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Albuterol Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/5 mL (473 mL): $43.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Albuterol Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $178.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (100): $334.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Albuterol Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $587.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $587.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130963\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aero-Vent (PH);</li>\n      <li>Aerolin (BR, CN, GR, QA);</li>\n      <li>Aeromol (TH);</li>\n      <li>Airmax (CO);</li>\n      <li>Airomir (AU, BE, DK, ES, FI, FR, GB, LU, NO, SE, TW, UY);</li>\n      <li>Asmacaire (PH);</li>\n      <li>Asmadil (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Asmalat (LB);</li>\n      <li>Asmalin Pulmoneb (PH);</li>\n      <li>Asmanol (ZW);</li>\n      <li>Asmatol (AR);</li>\n      <li>Asmavent (ZW);</li>\n      <li>Asmed (ZW);</li>\n      <li>Asmidon (JP);</li>\n      <li>Asmol (SG);</li>\n      <li>Asmol CFC-Free (AU);</li>\n      <li>Assal (MX);</li>\n      <li>Asthalin (IN, LB, LK, NZ, RO, ZW);</li>\n      <li>Asthalin HFA (HK);</li>\n      <li>Asthalin Inhaler (TZ);</li>\n      <li>Asthavent (AE, ZA);</li>\n      <li>Asvimol (PH);</li>\n      <li>Avedox-FC (MX);</li>\n      <li>Azmacon (ID);</li>\n      <li>Bajapres (CO);</li>\n      <li>Bemin (EC);</li>\n      <li>Bresaltec (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Brodil (BD);</li>\n      <li>Brodil HFA (BD);</li>\n      <li>Broncho-Spray (DE);</li>\n      <li>Bronchosol (TH);</li>\n      <li>Broncolin (MY, PH);</li>\n      <li>Brondisal (ID);</li>\n      <li>Bropil (CL);</li>\n      <li>Brytolin (PH);</li>\n      <li>Butalin (ET, JO, LB, SA);</li>\n      <li>Butamol (AR, AU, PY);</li>\n      <li>Butavent (MY);</li>\n      <li>Buto-Air (ES, MT);</li>\n      <li>Buto-Asma (BG, HK, PK, TH);</li>\n      <li>Butotal (CN);</li>\n      <li>Buventol (AE, AT, CZ, EE, LV, NO, SG, TW);</li>\n      <li>Buventol Easyhaler (TH);</li>\n      <li>Ciplabutol (EC);</li>\n      <li>Cotran (TW);</li>\n      <li>Cybutol (ID, LK);</li>\n      <li>Derihaler (ET, LK);</li>\n      <li>Durasol CR (LK);</li>\n      <li>Easyhaler Salbutamol (GB, IE);</li>\n      <li>Ecosal (BG, HR);</li>\n      <li>Etinoline (CN);</li>\n      <li>Farcolin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Farmarest (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Grafalin (ID);</li>\n      <li>Hivent DS (PH);</li>\n      <li>Huma-Salmol (HU);</li>\n      <li>Inbumed (MX);</li>\n      <li>Lebasma (ET);</li>\n      <li>Libretin (PH);</li>\n      <li>Medolin (SG);</li>\n      <li>Mozal (TW);</li>\n      <li>Nebsal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Respigen (NZ);</li>\n      <li>Sabutal (TW);</li>\n      <li>Salamol (CH, IE, MY);</li>\n      <li>Salapin (MT, NZ);</li>\n      <li>Salbetol (IN);</li>\n      <li>Salbo 2 (LK);</li>\n      <li>Salbron (ID);</li>\n      <li>Salbuflo (LK, PH);</li>\n      <li>Salbul (IE);</li>\n      <li>Salbulin (LU);</li>\n      <li>Salbutalan (MX);</li>\n      <li>Salbutamol (HU);</li>\n      <li>Salbutamol-GW (HU);</li>\n      <li>Salbutan (VE);</li>\n      <li>Salbutin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Salbutol (KR);</li>\n      <li>Salbutrim (IL);</li>\n      <li>Salbuven (ID);</li>\n      <li>Salbuvent (PE);</li>\n      <li>Salmaplon (IN);</li>\n      <li>Salmolin (BD);</li>\n      <li>Salomol (TW);</li>\n      <li>Saltam (ID);</li>\n      <li>Salvent (ZW);</li>\n      <li>Solia (TH);</li>\n      <li>Sultanol (AT, DE, JP);</li>\n      <li>Synvent HFA (HK);</li>\n      <li>Teoden (BR);</li>\n      <li>Unibron (MX);</li>\n      <li>Velutine (ID);</li>\n      <li>Venalax (PH);</li>\n      <li>Venderol (SG);</li>\n      <li>Venetlin (JP);</li>\n      <li>Ventamol (ID);</li>\n      <li>Venterol (TH);</li>\n      <li>Venteze (ZA, ZW);</li>\n      <li>Ventilan (CO, PT);</li>\n      <li>Ventilastin (LT, RO);</li>\n      <li>Ventilastin Novolizer (DE, FR);</li>\n      <li>Ventodisk (LU);</li>\n      <li>Ventol (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ventolin (AE, AR, AU, BE, BF, BG, BH, BJ, BS, BZ, CH, CI, CL, CU, CY, CZ, DO, EE, EG, ES, ET, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, YE, ZM, ZW);</li>\n      <li>Ventolin CFC-Free (AU);</li>\n      <li>Ventolin HFA (BB, BM);</li>\n      <li>Ventoline (DK, FI, FR, NO, SE);</li>\n      <li>Ventylor (UA);</li>\n      <li>Volmax (AE, BH, CY, EC, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zenmolin (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Zibil (MX);</li>\n      <li>Zomm (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. <i>Obstet Gynecol</i>. 2008;111(2 Pt 1):457-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Airomir (salbutamol) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.5% [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.083% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate inhalation solution 0.021% and 0.042% [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuterol sulfate syrup [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2919849\"></a>Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. <i>Ann Intern Med</i>. 1989;110(6):426-429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/2919849/pubmed\" target=\"_blank\" id=\"2919849\">2919849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartfield JM, Boenau IB, Lozon J, et al, &ldquo;Comparison of Metered Dose Inhaler and Oral Administration of Albuterol in the Outpatient Treatment of Infants and Children,&rdquo; <i>Am J Emerg Med</i>, 1995, 13(3):375-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/7755840/pubmed\" target=\"_blank\" id=\"7755840\">7755840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Batterink.2015\"></a>Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalemia in adults. <i>Cochrane Database Syst Rev</i>. 2015;10:CD010344.<span class=\"doi\">10.1002/14651858.CD010344.pub2</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boulton DW, Fawcett JP, and Fiddes TM, &quot;Transplacental Distribution of Salbutamol Enantiomers at Caesarian Section,&quot; <i>Br J Clin Pharmacol</i>,1997, 44(6):587-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/9431837/pubmed\" target=\"_blank\" id=\"9431837\">9431837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook P, Scarfone RJ, and Cook RT, &ldquo;Adenosine in the Termination of Albuterol-Induced Supraventricular Tachycardia,&rdquo; <i>Ann Emerg Med</i>, 1994, 24(2):316-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8037401/pubmed\" target=\"_blank\" id=\"8037401\">8037401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finnerty JP and Howarth PH, &ldquo;Paradoxical Bronchoconstriction With Nebulized Albuterol but not With Terbutaline,&rdquo; <i>Am Rev Respir Dis</i>, 1993, 148(2):512-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8342917/pubmed\" target=\"_blank\" id=\"8342917\">8342917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz RW, Kelly HW, Crowley MR, et al, &ldquo;Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children,&rdquo; <i>Pediatrics</i>, 1993, 92(5):666-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8414852/pubmed\" target=\"_blank\" id=\"8414852\">8414852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leikin JB, Linowiecki KA, Soglin DF, et al, &ldquo;Hypokalemia After Pediatric Albuterol Overdose: A Case Series,&rdquo; <i>Am J Emerg Med</i>, 1994, 12(1):64-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8285977/pubmed\" target=\"_blank\" id=\"8285977\">8285977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin R, Smith AJ, and Hergenroeder P, &ldquo;High Serum Albuterol Levels and Tachycardia in Adult Asthmatics Treated With High-Dose Continuously Aerosolized Albuterol,&rdquo; <i>Chest</i>, 1993, 103(1):221-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8417883/pubmed\" target=\"_blank\" id=\"8417883\">8417883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahajan M, Tucker J, and Dolgin J, &ldquo;Protocol for Management of Accidental Pediatric Albuterol Ingestions,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36:361.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10084465\"></a>Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? how safe? <i>Chest.</i> 1999;115(3):617-622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/10084465/pubmed\" target=\"_blank\" id=\"10084465\">10084465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manthous CA, Hall JB, Schmidt GA, et al, &ldquo;Metered-Dose Inhaler Versus Nebulized Albuterol in Mechanically Ventilated Patients,&rdquo; <i>Am Rev Respir Dis</i>, 1993, 148(6 Pt 1):1567-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8256902/pubmed\" target=\"_blank\" id=\"8256902\">8256902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik P, Hogan J, and Krikorian J, &ldquo;A Comparison of Bronchodilator Therapy Delivered by Nebulization and Metered-Dose Inhaler in Mechanically Ventilated Patients,&rdquo; <i>Chest</i>, 1999, 115(6):1653-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/10378564/pubmed\" target=\"_blank\" id=\"10378564\">10378564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics - 2002,&rdquo; <i>J Allergy Clin Immunol</i>, 2002, 110(5 Suppl):141-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/12542074/pubmed\" target=\"_blank\" id=\"12542074\">12542074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Callaghan C, Milner AD, and Swarbrick A, &ldquo;Nebulized Salbutamol Does Have a Protective Effect on Airways in Children Under One Year Old,&rdquo; <i>Arch Dis Child</i>, 1988, 63(5):479-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/3389861/pubmed\" target=\"_blank\" id=\"3389861\">3389861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papo MC, Frank J, and Thompson AE, &ldquo;A Prospective, Randomized Study of Continuous Versus Intermittent Nebulized Albuterol for Severe Status Asthmaticus in Children,&rdquo; <i>Crit Care Med</i>, 1993, 21(10):1479-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8403956/pubmed\" target=\"_blank\" id=\"8403956\">8403956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ProAir HFA (albuterol) [prescribing information]. Horsham, PA: Teva Speciality Pharmaceuticals LLC; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ProAir RespiClick (albuterol) [prescribing information]. Horsham, PA: Teva Respiratory; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Proventil HFA (albuterol) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp.; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Putcha N, Allon M. Management of hyperkalemia in dialysis patients. <i>Semin Dial</i>. 2007;20(5):431-439.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/17897250/pubmed\" target=\"_blank\" id=\"17897250\">17897250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part II,&rdquo; <i>J Allergy Clin Immunol</i>, 1985, 76(3):409-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/2863296/pubmed\" target=\"_blank\" id=\"2863296\">2863296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Parkin P, Rajan A, et al, &ldquo;High- Versus Low-Dose, Frequently Administered, Nebulized Albuterol in Children With Severe, Acute Asthma,&rdquo; <i>Pediatrics</i>, 1989, 83(4):513-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/2927990/pubmed\" target=\"_blank\" id=\"2927990\">2927990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Reider MJ, Canny G, et al, &ldquo;Nebulized Albuterol in Acute Childhood Asthma: Comparison of Two Doses,&rdquo; <i>Pediatrics</i>, 1990, 86(4):509-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/2216613/pubmed\" target=\"_blank\" id=\"2216613\">2216613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spiller HA, Ramoska EA, Henretig FM, et al, &ldquo;A Two-Year Retrospective Study of Accidental Pediatric Albuterol Ingestions,&rdquo; <i>Pediatr Emerg Care</i>, 1993, 9(6):338-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/8302698/pubmed\" target=\"_blank\" id=\"8302698\">8302698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Udezue E, D'Souza L, and Mahajan M, &ldquo;Hypokalemia After Normal Doses of Nebulized Albuterol (Salbutamol),&rdquo; <i>Am J Emerg Med</i>, 1995, 13(2):168-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/7893301/pubmed\" target=\"_blank\" id=\"7893301\">7893301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20956228\"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6)e239; <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation.</i> 2010;122(18)(suppl 3):S829-S861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span><span class=\"doi\">10.1161/CIRCULATIONAHA.110.971069</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ventolin (albuterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ventolin Diskus (salbutamol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiley JF 2nd, Spiller HA, Krenzelok EP, et al, &ldquo;Unintentional Albuterol Ingestion in Children,&rdquo; <i>Pediatr Emerg Care</i>, 1994, 10(4):193-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/7937293/pubmed\" target=\"_blank\" id=\"7937293\">7937293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong SL, Maltz HC. Albuterol for the treatment of hyperkalemia. <i>Ann Pharmacother</i>. 1999;33(1):103-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albuterol-salbutamol-drug-information/abstract-text/9972391/pubmed\" target=\"_blank\" id=\"9972391\">9972391</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9396 Version 227.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130976\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130977\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F131027\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F130981\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F131004\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F130982\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F130983\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671334\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130951\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F130935\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F20995164\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950005\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F130955\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F130954\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25816100\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131035\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130942\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130958\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130939\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298694\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130944\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130947\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130961\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16137852\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F130949\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130938\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F130957\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130960\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130963\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9396|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=albuterol-salbutamol-patient-drug-information\" class=\"drug drug_patient\">Albuterol (salbutamol): Patient drug information</a></li><li><a href=\"topic.htm?path=albuterol-salbutamol-pediatric-drug-information\" class=\"drug drug_pediatric\">Albuterol (salbutamol): Pediatric drug information</a></li></ul></div></div>","javascript":null}